首頁 > 市場調查報告書 > 醫療設備

體外診斷

市場調查報告書

商品編碼

2126409

罕見疾病生物標記檢測市場－策略分析與預測（2026-2035）

Rare Disease Biomarker Testing Market - Strategic Insights and Forecasts (2026-2035)

出版日期: 2026年08月10日 | 出版商:

Knowledge Sourcing Intelligence | 英文 175 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄

罕見疾病生物標記檢測市場預計將從 2026 年的 47.8 億美元成長到 2035 年的 96.9 億美元，複合年成長率為 8.2%。

罕見疾病生物標記檢測市場正經歷顯著的變革，其驅動力包括精準醫療的模式轉移、孤兒藥研發管線的擴展以及全基因測序在臨床實踐中日益廣泛的應用。這個市場演變的特點在於，人們逐漸認知到分子、生化、遺傳和細胞層面的生物標記對於罕見疾病的識別、診斷和管理至關重要，而生物標記檢測則在分子診斷和標靶治療選擇之間發揮關鍵的橋樑作用。次世代定序、多體學技術和人工智慧的融合使得罕見疾病的檢測和表徵能夠更快、更全面、更靈敏地進行。早期診斷已在臨床管理、患者預後和醫療資源利用方面展現出顯著的改善，從而擴展了基因組檢測在醫療系統中的應用範圍。同時，製藥公司正在藥物研發的早期階段就整合生物標記策略，這進一步強化了對涵蓋所有罕見疾病適應症的、檢驗的分子診斷的長期需求。隨著對次世代定序(NGS) 平台、多組體學整合和人工智慧驅動的分析工具的大量投資，罕見疾病生物標記檢測正在成為精準醫療和孤兒藥開發的基礎要素。

市場促進因素

精準醫療在罕見疾病管理中的日益普及是推動罕見疾病生物標記檢測市場發展的主要動力。由於精準醫療能夠基於分子層面的特徵分析，為患者配對標靶治療，生物標記檢測已成為重要的臨床工具。鑑於許多罕見疾病儘管病因不同，但臨床症狀卻十分相似，醫療機構正擴大將基因組檢測納入常規診斷流程。這種轉變不僅降低了診斷的不確定性，也為個人化治療策略的發展提供了可能。同時，製藥公司不斷拓展其標靶治療產品組合，從而增加了對能夠準確識別合格患者群體的標準化生物標記檢測的需求。因此，罕見疾病生物標記檢測的應用持續成長。次世代定序（NGS）在臨床診斷中的廣泛應用，透過提高診斷的準確性和效率，進一步加速了市場成長。 NGS能夠同時分析數百至數千個與罕見疾病相關的基因。臨床檢查室正從單基因順序檢測轉向全面的定序panel，從而提高了診斷率並縮短了整體檢測時間。定序技術成本的降低也推動了其在三級醫療機構和專業診斷中心的廣泛應用。這些技術進步增加了對能夠分析日益複雜的基因組資料集的先進生物資訊學平台的需求。隨著孤兒藥研發開發平臺的擴展，對分子診斷的依賴在整個藥物開發過程中不斷增強。申辦者擴大將基於生物標記的入組標準納入臨床試驗，以提高遺傳同質性患者群體治療效果的評估。因此，伴隨診斷的開發與治療藥物的商業化正變得緊密相關。政府支持的基因組醫學計畫正在加速公共醫療系統採用標準化生物標記檢測。國家精準醫療舉措正透過擴展基因組檢測基礎設施來促進遺傳疾病的早期發現。

市場限制因素

全面的基因測序、專業的實驗室基礎設施和先進的生物資訊技術高成本，持續限制資源匱乏的醫療體系對這些技術的廣泛應用。先進技術所需的巨額資金投入對小規模的醫療機構和發展中地區構成了障礙。許多罕見疾病缺乏可靠的臨床證據，阻礙了生物標記的檢驗，導致突變解讀和診斷信心的不確定性。許多罕見疾病缺乏強力的證據，為診斷結果的一致性帶來了挑戰。儘管臨床效用日益提升，但各國健保報銷制度的差異限制了病患獲得先進分子診斷服務的機會。不同地區保險覆蓋範圍的差異給診斷服務提供者帶來了不確定性，並限制了患者的就醫途徑。不同司法管轄區的監管複雜性也給尋求將新型診斷解決方案商業化的製造商帶來了合規負擔。

對生物標記技術和類型的深入了解

技術發展趨勢的特徵是全基因測序、多組體學整合和人工智慧輔助解讀的重要性日益凸顯。次世代定序(NGS) 能夠同時分析數百至數千個與罕見疾病相關的基因，從而提高診斷準確性並縮短整體檢測時間。對於需要快速獲得結果的特定突變檢測，PCR 仍然至關重要。微陣列分析繼續支持拷貝數變異的檢測。免疫檢測仍然是評估蛋白質和生化標記的關鍵。片段分析表明，神經系統疾病是生物標記檢測的最大領域之一，因為許多遺傳性神經發育障礙和神經退化性疾病表現出重疊的臨床症狀。在臨床異質性疾病中，全面的分子評估能夠提高診斷準確性，促使醫療專業人員擴大使用綜合定序panel，而不是進行順序的單一基因分析。血液仍然是主要的檢體類型，因為它具有低侵入性，並且能夠相容於多種分子檢測技術，包括DNA定序、RNA分析、數位PCR和生化標記評估。臨床診斷檢查室是關鍵的終端使用者群體，因為它們擁有專業的定序基礎設施、分子病理學專業知識以及進行複雜基因組分析所需的高級生物資訊能力。隨著人工智慧平台擴大輔助致病變異分類、表現型匹配和臨床報告，人工智慧的整合變得日益重要。機器學習演算法的不斷改進進一步提高了診斷結果在日益多樣化的患者群體中的一致性。

競爭格局與策略展望

競爭格局包括成熟的診斷和定序公司，以及專注於罕見疾病、基因組學和精準醫療的供應商。羅氏透過將藥物、分子診斷和伴隨診斷的開發整合到精準醫療生態系統中而脫穎而出，並透過擴展NGS能力、數位病理解決方案和先進的分子診斷技術，不斷強化其罕見疾病生物標記產品組合。 Illumina憑藉其全面的NGS技術組合，為全球臨床檢查室、研究機構和製藥公司提供服務，保持著戰略領先地位，並持續改進定序通量、分析準確性和工作流程自動化。賽默飛世爾科技憑藉其多樣化的分子診斷、定序技術和檢查室工作流程解決方案而脫穎而出，並透過將Ion Torrent定序、即時PCR 、數位PCR和生物資訊軟體整合到標準化診斷工作流程中，不斷擴展其綜合基因組學檢測能力。 Myliad Genetics專注於經臨床檢驗的基因檢測，擁有豐富的突變解讀經驗和專有的基因組資料庫，並透過先進的分子檢測方法不斷提升其遺傳疾病檢測能力。 QIAGEN 的獨特之處在於其將分子樣本技術、伴隨診斷、數位 PCR 和生物資訊解決方案整合到全面的精準醫療工作流程中。 Bio-Rad 則憑藉其高靈敏度的數位 PCR 技術和分子品管解決方案確立了強大的市場地位。兩家公司都在透過 NGS 平台、多組體學解決方案和人工智慧驅動的分析工具的創新來拓展其產品系列。在伴隨診斷發展和精準醫療需求的推動下，診斷設備製造商、製藥公司和研究機構之間的策略合作關係日益增加。近期一項重大進展是 Anthropic推出了「AI for Science」罕見疾病研究項目，該項目為研究人員和早期生物技術團隊提供價值高達 5 萬美元的 Claude API 積分。罕見疾病倡導組織已敦促美國食品藥物管理局(FDA) 重新思考臨床終點的定義、生物標記檢驗的進行方式、臨床試驗設計的實施方法以及罕見疾病諮詢委員會的改革。地理擴張仍然是重要的策略重點，各公司都將目光投向了快速成長的亞太地區和醫療基礎設施不斷完善的新興市場。

簡明結論

罕見疾病生物標記檢測市場預計將持續成長，這主要得益於精準醫療、孤兒藥研發和技術創新三者的融合。從單一基因順序檢測轉向全面的多組體學分析，標誌著罕見疾病管理方式的根本性變革。儘管高成本、證據不足和保險報銷差異等挑戰依然存在，但對技術、夥伴關係和證據產生的策略性投資正為市場領導帶來持續的競爭優勢。長期市場前景依然樂觀，罕見疾病生物標記檢測可望發展成為精準醫療的基礎要素，為全球醫療體系的早期診斷、治療方案選擇和患者預後改善提供支持。

本報告的主要益處：

深入分析：詳細分析涵蓋各個地區、客戶群、政策、社會經濟因素、消費者偏好和產業。
競爭格局：我們將了解主要公司的策略部署，並確定最佳的市場進入方式。
市場促進因素與未來趨勢：我們評估影響市場的關鍵成長要素和新興趨勢。
實用建議：我們支援制定策略決策，以開發新的收入來源。
適用於廣泛的使用者群體：非常適合新創公司、研究機構、顧問公司、中小企業和大型企業。

你用它來做什麼？

產業和市場分析、商業機會評估、產品需求預測、打入市場策略、地理擴張、資本投資決策、法律規範和影響、新產品開發以及競爭影響。

分析範圍

歷史資料（2021-2024 年）、基準年（2025 年）和預測資料（2026-2035 年）
成長機會、挑戰、供應鏈前景、法規結構、顧客行為和趨勢分析。
競爭對手定位、策略和市場佔有率分析
營收成長率及預測分析：依業務板塊及地區（國家）分類
企業概況（策略、產品、財務資訊、關鍵趨勢等）

市場定義和範圍
罕見疾病概述
生物標記檢測在罕見疾病診斷和治療中的作用
產業變化
主要市場趨勢
實際成果值市場規模分析
市場預測
疾病負擔與未滿足的診斷需求
罕見病患疾病率分析
已確診患者族群的分析
罕見疾病診斷中的病人歷程分析
測試數量分析

第4章市場動態

市場促進因素
市場限制因素
市場機遇
市場挑戰

第5章行業情勢

產業價值鏈分析
定價分析
還款狀態

第6章：創新趨勢

新型生物標記發現技術
多組體學技術的進步
產品創新
新型罕見疾病生物標記檢測的流程分析
對支持生物標記檢驗的臨床試驗進行分析
人工智慧在生物標記發現與解讀的應用
將數位醫療技術融入罕見疾病診斷

第7章監理情勢

法律規範
核准流程
合規要求

第8章：全球罕見疾病生物標記檢測市場：展望分析

分析：按技術平台
分析：依生物標記類型
分析：依檢體類型
分析：透過測試方法
分析：透過臨床應用
分析：按最終用戶

第9章全球罕見疾病生物標記檢測市場：細分市場分析

依生物標誌類型
- 基因生物標記
- 蛋白質體學生物標記
- RNA生物標記
- DNA生物標記
- 其他
透過技術
- 次世代定序（NGS）
- 聚合酵素鏈鎖反應（PCR）
- 桑格定序
- 微陣列分析
- 免疫測量
- 其他分子技術
依檢體類型
- 血
- 組織
- 唾液和口腔黏膜拭子
- 尿
- 腦脊髓液
- 其他生物檢體
疾病特異性
- 罕見遺傳疾病
- 罕見神經系統疾病
- 罕見代謝性疾病
- 罕見血液疾病
- 罕見心血管疾病
- 其他罕見疾病
臨床應用
- 篩檢
- 早期診斷
- 對疾病的最終診斷
- 預後評估
- 治療方案和後續觀察
最終用戶
- 醫院
- 臨床診斷檢測實驗室
- 學術研究機構
- 其他

第10章：全球罕見疾病生物標記檢測市場：區域分析

北美洲
歐洲
亞太地區
南美洲
中東和非洲

第11章：全球罕見疾病生物標記檢測市場：國別分析

美國
加拿大
德國
英國
法國
義大利
西班牙
日本
中國
印度
澳洲
巴西
沙烏地阿拉伯
南非

第12章競爭格局

市佔率分析
策略趨勢
併購、合作與聯盟
新產品發布

第13章：公司簡介

F. Hoffmann-La Roche Ltd.
Illumina, Inc.
Thermo Fisher Scientific Inc.
Myriad Genetics, Inc.
QIAGEN NV
Bio-Rad Laboratories, Inc.
Agilent Technologies, Inc.
Eurofins Scientific SE
Natera, Inc.
Invitae Corporation

第14章：全球罕見疾病生物標記檢測市場：商業預測分析

第15章：投資與資金籌措分析

創業投資趨勢
政府資金
研發投資

第16章：未來展望

主要成長機遇
未來產業趨勢

簡介目錄

Product Code: KSI-009120

The Rare Disease Biomarker Testing Market is expected to grow at a CAGR of 8.2% from a market value of USD 4.78 billion in 2026 to USD 9.69 billion in 2035.

The rare disease biomarker testing market is undergoing significant transformation driven by the paradigm shift toward precision medicine, the expanding orphan drug pipeline, and the growing integration of comprehensive genomic sequencing into clinical practice. The market's evolution is characterized by the recognition that molecular, biochemical, genetic, and cellular biomarkers are essential for identifying, diagnosing, and managing rare diseases, with biomarker testing serving as a critical link between molecular diagnosis and targeted therapeutic selection. The convergence of next-generation sequencing, multi-omics technologies, and artificial intelligence is enabling faster, more comprehensive, and increasingly sensitive rare disease detection and characterization. Healthcare systems are expanding genomic testing capabilities as earlier diagnosis demonstrates measurable improvements in clinical management, patient outcomes, and healthcare resource utilization. Pharmaceutical sponsors are simultaneously incorporating biomarker strategies into earlier stages of drug development, strengthening long-term demand for validated molecular diagnostics across orphan disease indications. The market is witnessing significant investment in NGS platforms, multi-omics integration, and AI-enabled interpretation tools, positioning rare disease biomarker testing as a foundational component of precision healthcare and orphan drug development.

Market Drivers

The increasing integration of precision medicine into rare disease management represents the primary driver for the rare disease biomarker testing market. Precision medicine relies on molecular characterization to match patients with targeted therapies, making biomarker testing an indispensable clinical tool. Healthcare providers are increasingly incorporating genomic testing into routine diagnostic pathways because many rare disorders share similar clinical symptoms despite distinct genetic origins. This transition reduces diagnostic ambiguity while enabling personalized treatment strategies. Pharmaceutical developers are simultaneously expanding targeted therapeutic portfolios, increasing demand for standardized biomarker assays that accurately identify eligible patient populations, resulting in sustained growth in rare disease biomarker testing utilization. The expansion of next-generation sequencing in clinical diagnostics is further accelerating market growth through improved diagnostic yield and efficiency. NGS enables simultaneous analysis of hundreds or thousands of genes associated with rare disorders. Clinical laboratories are increasingly replacing sequential single-gene testing with comprehensive sequencing panels because they improve diagnostic yield and reduce overall testing time. The growing affordability of sequencing technologies further supports broader adoption across tertiary hospitals and specialized diagnostic centers. These technological improvements strengthen demand for advanced bioinformatics platforms capable of interpreting increasingly complex genomic datasets. The growing rare disease drug development pipeline is increasing dependence on molecular diagnostics throughout therapeutic development. The expanding orphan drug pipeline increases dependence on molecular diagnostics throughout therapeutic development. Sponsors are increasingly incorporating biomarker-defined inclusion criteria into clinical trials because genetically homogeneous patient populations improve treatment response evaluation. Companion diagnostic development therefore becomes strategically aligned with therapeutic commercialization. Government-supported genomic medicine programs are strengthening adoption of standardized biomarker testing across public healthcare systems. National precision medicine initiatives promote earlier identification of inherited diseases through expanded genomic testing infrastructure.

Market Restraints

High costs associated with comprehensive genomic sequencing, specialized laboratory infrastructure, and advanced bioinformatics continue limiting widespread adoption in resource-constrained healthcare systems. The significant financial investment required for advanced technologies creates barriers for smaller facilities and developing regions. Limited clinical evidence for numerous ultra-rare disorders reduces biomarker validation, creating uncertainty in variant interpretation and diagnostic confidence. The lack of robust evidence for many rare conditions creates challenges for consistent interpretation. Reimbursement variability across countries restricts patient access to advanced molecular diagnostics despite increasing clinical utility. Inconsistent coverage across regions creates uncertainty for diagnostic providers and limits patient access. Regulatory complexities across different jurisdictions create compliance burdens for manufacturers seeking to commercialize new diagnostic solutions.

Technology and Biomarker Type Insights

The technology landscape is characterized by the growing importance of comprehensive genomic sequencing, multi-omics integration, and AI-enabled interpretation. NGS enables simultaneous analysis of hundreds or thousands of genes associated with rare disorders, improving diagnostic yield and reducing overall testing time. PCR remains important for focused mutation detection where rapid turnaround is prioritized. Microarray analysis continues supporting copy number variation detection. Immunoassays remain essential for protein and biochemical biomarker assessment. The segment analysis reveals that neurological disorders represent one of the largest areas of biomarker testing because many inherited neurodevelopmental and neurodegenerative diseases share overlapping clinical presentations. Healthcare providers are increasingly utilizing comprehensive sequencing panels rather than sequential single-gene analysis because broader molecular evaluation improves diagnostic yield in clinically heterogeneous disorders. Blood remains the primary sample type because collection is minimally invasive and supports multiple molecular testing technologies, including DNA sequencing, RNA analysis, digital PCR, and biochemical biomarker assessment. Clinical diagnostic laboratories constitute the leading end-user segment because they possess specialized sequencing infrastructure, molecular pathology expertise, and advanced bioinformatics capabilities required for complex genomic interpretation. The integration of AI is becoming increasingly important because AI platforms are increasingly supporting pathogenic variant classification, phenotype matching, and clinical reporting. Continuous refinement of machine learning algorithms further enhances diagnostic consistency across increasingly diverse patient populations.

Competitive and Strategic Outlook

The competitive landscape features established diagnostics and sequencing companies alongside specialized rare disease, genomic, and precision medicine providers. Roche differentiates itself through the integration of pharmaceuticals, molecular diagnostics, and companion diagnostic development within a single precision medicine ecosystem, continuing to strengthen its rare disease biomarker portfolio by expanding NGS capabilities, digital pathology solutions, and advanced molecular diagnostics. Illumina maintains strategic leadership through its comprehensive NGS technology portfolio, which serves clinical laboratories, research institutions, and pharmaceutical developers worldwide, continuously improving sequencing throughput, analytical accuracy, and workflow automation. Thermo Fisher Scientific distinguishes itself through its diversified molecular diagnostics, sequencing technologies, and laboratory workflow solutions, expanding integrated genomic testing capabilities by combining Ion Torrent sequencing, real-time PCR, digital PCR, and bioinformatics software into standardized diagnostic workflows. Myriad Genetics focuses on clinically validated genetic testing supported by extensive variant interpretation expertise and proprietary genomic databases, continuing to enhance hereditary disease testing through advanced molecular assays. QIAGEN differentiates itself by integrating molecular sample technologies, companion diagnostics, digital PCR, and bioinformatics solutions into comprehensive precision medicine workflows. Bio-Rad has established a strong position through highly sensitive digital PCR technologies and molecular quality control solutions. Companies are pursuing product portfolio expansion through innovation in NGS platforms, multi-omics solutions, and AI-enabled interpretation tools. Strategic collaborations between diagnostic manufacturers, pharmaceutical companies, and research institutions are increasing, driven by the need for companion diagnostic development and precision medicine. Recent key developments include Anthropic launching its AI for Science rare disease research program, offering up to $50,000 in Claude API credits to researchers and early-stage biotech teams. Rare disease advocates urged the US FDA to rethink how it sets clinical endpoints, validates biomarkers, designs trials, and reforms advisory committees for small patient populations. Geographic expansion remains a key strategic priority, with companies targeting rapidly growing Asia Pacific and emerging markets where healthcare infrastructure is expanding.

Short Conclusion

The rare disease biomarker testing market is positioned for sustained growth driven by the convergence of precision medicine, orphan drug development, and technological innovation. The transition from sequential single-gene testing toward comprehensive multi-omics profiling represents a fundamental shift in rare disease management. While challenges related to high costs, limited evidence, and reimbursement variability persist, strategic investments in technology, partnerships, and evidence generation are creating durable competitive advantages for market leaders. The long-term market outlook remains positive, with rare disease biomarker testing evolving into a foundational component of precision healthcare, supporting earlier diagnosis, therapeutic selection, and improved patient outcomes across global healthcare systems.

Key Benefits of this Report

Insightful Analysis: Detailed market insights across regions, customer segments, policies, socio-economic factors, consumer preferences, and industry verticals.
Competitive Landscape: Understand strategic moves by key players to identify optimal market entry approaches.
Market Drivers and Future Trends: Assess major growth forces and emerging developments shaping the market.
Actionable Recommendations: Support strategic decisions to unlock new revenue streams.
Caters to a Wide Audience: Suitable for startups, research institutions, consultants, SMEs, and large enterprises.

What Businesses Use Our Reports For

Industry and market insights, opportunity assessment, product demand forecasting, market entry strategy, geographical expansion, capital investment decisions, regulatory analysis, new product development, and competitive intelligence.

Report Coverage

Historical data from 2021 to 2024, Base year 2025, and Forecast years from 2026 to 2035
Growth opportunities, challenges, supply chain outlook, regulatory framework, and trend analysis
Competitive positioning, strategies, and market share evaluation, and trade analysis
Revenue growth and forecast assessment across segments and regions
Company profiling including strategies, products, financials, and key developments

1. Executive Summary

1.1 Market Snapshot
1.2 Key Findings
1.3 Analyst Insights
1.4 Strategic Recommendations

2. Research Methodology

2.1 Research Design
2.2 Data Collection Methodology
2.3 Market Size Estimation
2.4 Forecasting Model
2.5 Assumptions & Limitations

3. Global Rare Disease Biomarker Testing Market Overview, Size & Forecast

3.1 Market Definition & Scope
3.2 Rare Disease Overview
3.3 Role of Biomarker Testing in Rare Disease Diagnosis and Management
3.4 Industry Evolution
3.5 Key Market Trends
3.6 Historical Market Size Analysis (2021-2025)
3.7 Market Forecast (2026-2035)
3.8 Disease Burden & Unmet Diagnostic Needs
3.9 Rare Disease Prevalence Analysis
3.10 Diagnosed Patient Population Analysis
3.11 Patient Journey Analysis for Rare Disease Diagnosis
3.12 Testing Volume Analysis

4. Market Dynamics

4.1 Market Drivers
4.2 Market Restraints
4.3 Market Opportunities
4.4 Market Challenges

5. Industry Landscape

5.1 Industry Value Chain Analysis
5.2 Pricing Analysis
5.3 Reimbursement Landscape

6. Innovation Landscape

6.1 Emerging Biomarker Discovery Technologies
6.2 Advances in Multi-Omics Technologies
6.3 Product Innovation
6.4 Pipeline Analysis of Novel Rare Disease Biomarker Tests
6.5 Clinical Trial Analysis Supporting Biomarker Validation
6.6 Artificial Intelligence in Biomarker Discovery and Interpretation
6.7 Digital Health Integration for Rare Disease Diagnostics

7. Regulatory Landscape

7.1 Regulatory Framework
7.2 Approval Pathways
7.3 Compliance Requirements

8. Global Rare Disease Biomarker Testing Market Landscape Analysis

8.1 Analysis by Technology Platform
8.2 Analysis by Biomarker Type
8.3 Analysis by Sample Type
8.4 Analysis by Testing Methodology
8.5 Analysis by Clinical Application
8.6 Analysis by End User

9. Global Rare Disease Biomarker Testing Market Segment Analysis (2021-2035)

9.1 By Biomarker Type
- 9.1.1 Genomic Biomarkers
- 9.1.2 Proteomic Biomarkers
- 9.1.3 RNA Biomarkers
- 9.1.4 DNA Biomarkers
- 9.1.5 Others
9.2 By Technology
- 9.2.1 Next-Generation Sequencing (NGS)
- 9.2.2 Polymerase Chain Reaction (PCR)
- 9.2.3 Sanger Sequencing
- 9.2.4 Microarray Analysis
- 9.2.5 Immunoassays
- 9.2.6 Other Molecular Technologies
9.3 By Sample Type
- 9.3.1 Blood
- 9.3.2 Tissue
- 9.3.3 Saliva & Buccal Swab
- 9.3.4 Urine
- 9.3.5 Cerebrospinal Fluid
- 9.3.6 Other Biological Samples
9.4 By Disease
- 9.4.1 Rare Genetic Disorders
- 9.4.2 Rare Neurological Disorders
- 9.4.3 Rare Metabolic Disorders
- 9.4.4 Rare Hematological Disorders
- 9.4.5 Rare Cardiovascular Disorders
- 9.4.6 Other Rare Diseases
9.5 By Clinical Application
- 9.5.1 Screening
- 9.5.2 Early Diagnosis
- 9.5.3 Disease Confirmation
- 9.5.4 Prognostic Assessment
- 9.5.5 Treatment Selection and Monitoring
9.6 By End User
- 9.6.1 Hospitals
- 9.6.2 Clinical Diagnostic Laboratories
- 9.6.3 Academic & Research Institutes
- 9.6.4 Others

10. Global Rare Disease Biomarker Testing Market Geographical Analysis (2021-2035)

10.1 North America
10.2 Europe
10.3 Asia-Pacific
10.4 South America
10.5 Middle East & Africa

11. Global Rare Disease Biomarker Testing Market Country Analysis (2021-2035)

11.1 United States
11.2 Canada
11.3 Germany
11.4 United Kingdom
11.5 France
11.6 Italy
11.7 Spain
11.8 Japan
11.9 China
11.10 India
11.11 Australia
11.12 Brazil
11.13 Saudi Arabia
11.14 South Africa

12. Competitive Landscape

12.1 Market Share Analysis
12.2 Strategic Developments
12.3 Mergers & Acquisitions, Partnerships & Collaborations
12.4 Product Launches

13. Company Profiles

13.1 F. Hoffmann-La Roche Ltd.
- 13.1.1 Company Overview
- 13.1.2 Financials
- 13.1.3 Product Portfolio
- 13.1.4 Recent Developments
13.2 Illumina, Inc.
13.3 Thermo Fisher Scientific Inc.
13.4 Myriad Genetics, Inc.
13.5 QIAGEN N.V.
13.6 Bio-Rad Laboratories, Inc.
13.7 Agilent Technologies, Inc.
13.8 Eurofins Scientific SE
13.9 Natera, Inc.
13.10 Invitae Corporation